参考文献： 1.ICH Steering Committee, Harmonised Tripartite
Guideline Q8: Pharmaceutical Development. August, 2009 2.ICH Steering Committee. Harmonised Tripartite
Guideline Q1A: Stability Testing of New Drug Substances and Products. 2003 3.ICH Steering Committee. Harmonised Tripartite
Guideline Q3D: Guideline for Elemental Impurities. 2014 4.ICH Steering Committee. Harmonised Tripartite
Guideline M7: Assessment and Control of DNA Reactive (Mutagenic) Impurities in
Pharmaceuticals to Limit Potential Carcinogenic Risk. 2017 5.国家食品药品监督管理总局.《化学药品新注册分类申报资料要求（试行）》（2016 年第 80 号） 6.化学药品注射剂基本技术要求（试行）(国食药监注〔2008〕7 号) 7.国家食品药品监督管理总局药品审评中心《灭菌/无菌工艺验证指导原则》（征求意见稿）（2013 年 8 月） 8.国家药品监督管理局.《除菌过滤技术及应用指南》（2018 年第 85 号） 9.国家食品药品监督管理总局.《化学药物（原料药和制剂）稳定性研究技术指导原则（修订）》（2015 年第 3 号） 10.国家食品药品监督管理总局.《化学药品注射剂与塑料包装材料相容性研究技术指导原则（试行）》（国食药监注〔2012〕267 号） 11.国家食品药品监督管理总局.《化学药品注射剂与药用玻璃包装容器相容性研究技术指导原则（试行）》（2015 年第 40 号） 12.国家食品药品监督管理总局.《化学药品与弹性体密封件相容性研究技术指导原则（试行）》（2018 年第 14 号） 13.国家药品监督管理局药品审评中心.《化学仿制药注册批生产规模的一般性要求（试行）》（2018 年 6 月） 14.国家药品监督管理局.《化学仿制药参比制剂遴选与确定程序》（2019 年第 25 号） 15.国家食品药品监督管理局.《关于加强药用玻璃包装注射剂药品监督管理的通知》(食药监办注〔2012〕132 号) 16.Food and Drug Administration, Center for Drug
Evaluation and Research (CDER), Office of Pharmaceutical Quality. Manual of
Policies and Procedures (MAPP), Policy and Procedures, 5040.1, Product Quality
Microbiology Information in the Common Technical Document - Quality (CTD-Q). January 2017 17.Food and Drug Administration, Center for Drug
Evaluation and Research (CDER). Guidance for Industry: ANDA Submissions –
Refuse-to-Receive Standards. December, 2016 18.Food and Drug Administration, Center for Drug
Evaluation and Research (CDER). Guidance for Industry: ANDA Submissions –
Refuse to Receive for Lack of Justification of Impurity Limits. August 2016 19.Food and Drug Administration, Center for Drug
Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM).
Guidance for Industry for the Submission Documentation for Sterilization
Process Validation in Applications for Human and Veterinary Drug Products.
November 1994 20.Food and Drug Administration, Center for Drug
Evaluation and Research (CDER) and Center for Biologics Evaluation and Research
(CBER). Guidance for Industry: Allowable Excess Volume and Labeled Vial Fill
Size in Injectable Drug and Biological Products. June 2015 21.Food and Drug Administration, Center for Biologics
Evaluation and Research, Center for Drug Evaluation and Research, Center for
Devices and Radiological Health, and Center for Veterinary Medicine. Guidance
for Industry: Container and Closure System Integrity Testing in Lieu of
Sterility Testing as a Component of the Stability Protocol for Sterile
Products. February 2008 22.Food and Drug Administration, Center for Drug
Evaluation and Research (CDER). Guidance for Industry: Changes to an Approved
NDA or ANDA. April 2004 23.Food and Drug Administration, Center for Drug
Evaluation and Research (CDER). Guidance for Industry: ANDAs: Stability Testing
of Drug Substances and Products, Questions and Answers. May 2014 24.USP <1207>、<1207.1>、<1207.2>、<1207.3> 25.European Medicines Agency, Committee for Medicinal
Products for Human Use (CHMP). EMA/CHMP/QWP/799402/2011: Reflection Paper on
the Pharmaceutical Development of Intravenous Medicinal Products Containing
Active Substances Solubilised in Micellar Systems. 26.European Medicines Agency, Committee for Medicinal
Products for Human Use (CHMP). Guideline on the Investigation of
Bioequivalence. January 2010 27.Health Canada, Health Products and Food Branch.
GUIDANCE FOR INDUSTRY: Pharmaceutical Quality of Aqueous Solutions. February
2008 28.Food and Drug Administration, Center for Drug Evaluation
andResearch (CDER). Guidances（Drugs）：Generics: https:// www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064995.htm 29.Food and Drug Administration, Center for Drug
Evaluation andResearch (CDER). Generic Drug Development:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/How DrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm142112.htm 30.Food and Drug Administration, Center for Drug
Evaluation and Research (CDER), Office of Generic Drugs. Filing Review of
Abbreviated New Drug Applications, MAPP 5200.14. September 2017. 31.European Medicines Agency, Committee for Proprietary
Medicine Products. Note for Guidance on In-use Stability Testing of Human
Medicine Products. September 2001. 32.European Medicines Agency, Committee for Proprietary Medicine Products. Note for Guidance on Inclusion of Antioxidants and Antimicrobial Preservatives in Medicine Products. January 1998. |
